Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo

Cancer Research

Volumn 63, Issue 10, 2003, Pages 2513-2517

  Maggiorella, Laurence ^a   Deutsch, Eric ^a   Frascogna, Valérie ^a   Chavaudra, Nicole ^a   Jeanson, Laurence ^a   Milliat, Fabien ^a   Eschwege, François ^a   Bourhis, Jean ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; DNA DEPENDENT PROTEIN KINASE; KU ANTIGEN; PROTEIN P53; ROSCOVITINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CELL CYCLE; CONTROLLED STUDY; DNA REPAIR; DNA STRAND BREAKAGE; ENZYME ACTIVITY; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MALE; MICRONUCLEUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PULSED FIELD GEL ELECTROPHORESIS; RADIOSENSITIVITY; SCID MOUSE; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, NUCLEAR; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; COMBINED MODALITY THERAPY; DNA HELICASES; DNA REPAIR; DNA, NEOPLASM; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PURINES; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0038519961     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Morgan, D. O. Principles of CDK regulation. Nature (Lond.), 374: 131-134, 1995.
2. Garrett, M. D., and Fattaey, A. CDK inhibition and cancer therapy. Curr. Opin. Genet. Dev., 9: 104-111, 1999.
3. Kaubisch, A., and Schwartz, G. K. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development. Cancer J., 6: 192-212, 2000.
4. Meijer, L., Bordne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, M., Delcros, J-G., and Moulinoux, J-P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2, and cdk5. Eur. J. Biochem., 243: 527-536, 1997.
5. Hajduch, M., Havlieek, L., Vesely, J., Novotny, R., Mihal, V., and Strnad, M. Synthetic cyclin dependent kinase inhibitors. New generation of potent anti-cancer drugs. Adv. Exp. Med. Biol., 457: 341-353, 1999.
6. Mgbonyebi, O. P., Russo, J., and Russo, I. H. Roscovitne induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res., 59: 1903-1910, 1999.
7. David-Pfeuty, T. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nuclear fragmentation in human untransformed and tumor-derived cells. Oncogene, 18: 7409-7422, 1999.
8. Somerville, L., and Cory, J. G. Enhanced roscovitine-induced apoptosis is mediated by a caspase-3-like activity in deoxyadenosine-resistant mouse leukemia L1210 cells. Anticancer Res., 20: 3347-3355, 2000.
9. Lu, W., Chen, L., Peng, Y., and Chen, J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene, 20: 3206-3216, 2001.
10. Blaydes, J. P., Craig, A. L., Wallace, M., Ball, H. M., Traynor, N. J., Gibbs, N. K., and Hupp, T. R. Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. Oncogene, 19: 3829-3839, 2000.
11. Langdon, S. P., Hendriks, H. R., Braakhuis, B. J., Pratesi, G., Berger, D. P., Fodstad, O., Fiebig, H. H., and Boven, E. Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study. Ann. Oncol., 5: 415-422, 1994.
12. Champion, A. R., Hanson, J. A., Court, J. B., and Venables, S. E. The micronucleus assay: an evaluation of its use in determining radiosensitivity in vitro. Mutagenesis, 10: 203-238, 1995.
13. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
14. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
15. Kao, G. D., McKenna, W. G., and Yen, T. J. Detection of repair activity during the DNA damage-induced G2 delay in human cancer cells. Oncogene, 20: 3486-3496, 2001.
16. Zaugg, K., Rocha, S., Resch, H., Hegyi, I., Oehler, C., Glanzmann, C., Fabbro, D., Bodis, S., and Pruschy, M. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412. Cancer Res., 61: 732-738, 2001.
17. DiBiase, S. J., Zeng, Z. C., Chen, R., Hyslop, T., Curran, W. J., Jr., and Iliakis, G. DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. Cancer Res., 60: 1245-1253, 2000.
18. Takata, M., Sasaki, M. S., Sonoda, E., Morrison, C., Hashimoto, M., Utsumi, H., Yamaguchi-Iwai, Y., Shinohara, A., and Takeda, S. Homologous recombination and non-homologous recombination end-joining pathways of DNA double strand break repair have overlapping roles in maintenance of chromosomal integrity in vertebrate cells. EMBO J., 17: 5497-5508, 1998.
19. Smith, G. C., and Jackson, S. P. the DNA-dependent protein kinase. Genes Dev., 13: 916-934, 1999.
20. Bible, K. C., Bible, R. H., Jr., Kottke, T. J., Svingen, P. A., Xu, K., Pang, Y. P., Hajdu, E., and Kaufmann, S. H. Flavopiridol binds to duplex DNA. Cancer Res., 60: 2419-2428, 2000.